Bristol-Myers Squibb Company (BMY) Shares Sold by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. reduced its position in Bristol-Myers Squibb Company (NYSE:BMY) by 87.6% during the first quarter, Holdings Channel reports. The fund owned 18,060 shares of the biopharmaceutical company’s stock after selling 127,542 shares during the period. Braun Stacey Associates Inc.’s holdings in Bristol-Myers Squibb Company were worth $982,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in BMY. Parsec Financial Management Inc. raised its position in shares of Bristol-Myers Squibb Company by 6.8% in the first quarter. Parsec Financial Management Inc. now owns 7,447 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 475 shares during the last quarter. Everett Harris & Co. CA raised its position in shares of Bristol-Myers Squibb Company by 9.4% in the first quarter. Everett Harris & Co. CA now owns 9,328 shares of the biopharmaceutical company’s stock worth $507,000 after buying an additional 800 shares during the last quarter. Investment Counsel Inc. raised its position in shares of Bristol-Myers Squibb Company by 17.0% in the first quarter. Investment Counsel Inc. now owns 28,882 shares of the biopharmaceutical company’s stock worth $1,571,000 after buying an additional 4,190 shares during the last quarter. Kanawha Capital Management LLC raised its position in shares of Bristol-Myers Squibb Company by 3.6% in the first quarter. Kanawha Capital Management LLC now owns 70,078 shares of the biopharmaceutical company’s stock worth $3,811,000 after buying an additional 2,403 shares during the last quarter. Finally, Physicians Financial Services Inc. raised its position in shares of Bristol-Myers Squibb Company by 0.4% in the first quarter. Physicians Financial Services Inc. now owns 9,929 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 39 shares during the last quarter. 69.75% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 55.22 on Tuesday. The firm has a market capitalization of $90.97 billion, a P/E ratio of 19.18 and a beta of 1.19. The company has a 50-day moving average of $54.37 and a 200 day moving average of $54.99. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $77.12.

Bristol-Myers Squibb Company (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $0.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.12. Bristol-Myers Squibb Company had a net margin of 24.22% and a return on equity of 31.86%. The business had revenue of $4.93 billion for the quarter, compared to analysts’ expectations of $4.75 billion. During the same quarter last year, the firm earned $0.74 EPS. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. Equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.95 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th will be given a dividend of $0.39 per share. The ex-dividend date is Wednesday, July 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.83%. Bristol-Myers Squibb Company’s dividend payout ratio is currently 54.17%.

COPYRIGHT VIOLATION WARNING: This article was posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/2654225/bristol-myers-squibb-company-bmy-shares-sold-by-braun-stacey-associates-inc.html.

A number of equities analysts recently weighed in on the stock. BidaskClub raised shares of Bristol-Myers Squibb Company from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Vetr raised shares of Bristol-Myers Squibb Company from a “buy” rating to a “strong-buy” rating and set a $58.88 target price for the company in a research note on Monday, June 5th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $64.00 target price on shares of Bristol-Myers Squibb Company in a research note on Monday, June 5th. BMO Capital Markets lowered shares of Bristol-Myers Squibb Company from a “market perform” rating to an “underperform” rating and set a $47.00 target price for the company. in a research note on Wednesday, May 3rd. Finally, Robert W. Baird assumed coverage on shares of Bristol-Myers Squibb Company in a research note on Tuesday, April 25th. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $62.41.

In other Bristol-Myers Squibb Company news, Director Lamberto Andreotti sold 34,000 shares of Bristol-Myers Squibb Company stock in a transaction that occurred on Tuesday, March 28th. The shares were sold at an average price of $56.17, for a total transaction of $1,909,780.00. Following the transaction, the director now owns 986,112 shares of the company’s stock, valued at approximately $55,389,911.04. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders have sold 85,000 shares of company stock worth $4,675,000. Insiders own 0.23% of the company’s stock.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.